4/21/2022
MD’s interested in saving significantly on the vaccine for infants Vaxelis™, may do so through an MPPG membership.
Independent practices as well as large groups may join Medical Practice Purchasing Group at no fee for discounts on vaccines they need to immunize patients from infancy through adulthood. Vaxelis™ is an infant vaccine developed in a collaborative effort between Merck and Sanofi Pasteur to reduce the number of injections for infants. Vaxelis™ is a state of the art hexavalent combination vaccine designed to prevent Diphtheria, Tetanus, Pertussis, Polio, Haemophilus influenza type B, and Hepatitis B. Although none of the antigen components are new ( DTaP-IPV-Hib-HepB ) their combination is new and a welcome improvement. Vaxelis™ was approved by the FDA in 2018 and recommended unanimously by the ACIP in June 2019.